The Patent Finder

Gi Innovation, Inc.

12 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Jul 2039
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jul 2, 2027
    The maintenance fee for Pharmaceutical Composition for Cancer Treatment Comprising Fusion Protein Including IL-2 Protein and CD80 Protein and Anticancer Drug (US 11,857,601) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 12,410,233Extracellular domain of alpha subunit of IgE Fc receptor, pharmaceutical composition comprising same and method for producing same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,492,384Fusion Protein Comprising IL-2 Protein and CD80 Protein, and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 11,857,601Pharmaceutical Composition for Cancer Treatment Comprising Fusion Protein Including IL-2 Protein and CD80 Protein and Anticancer Drug
In force
 · High confidence
In forceHigh confidence
US 12,286,464Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,639,383Pharmaceutical Composition for Treatment of Cancer, Comprising an Immune Checkpoint Inhibitor Antibody and a Fusion Protein Comprising an IL-2 Mutant and a CD80 Extracellular Domain
In force
 · High confidence
In forceHigh confidence
US 12,291,555Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,128,076Composition Comprising Probiotics and Polypeptide Having Binding Affinity for Ige and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,409,203Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of IGE FC receptor, and pharmaceutical composition comprising same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,478,675Pharmaceutical composition for enhancing radiotherapy comprising fusion protein containing IL-2 protein and CD80 protein
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,692,307Pharmaceutical Composition for Treatment of Cancer, Comprising an Immune Checkpoint Inhibitor Antibody and a Fusion Protein Comprising an IL-2 Mutant and a CD80 Extracellular Domain
In force
 · Medium confidence
In forceMedium confidence
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

9 pending

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited